CD28 Ligation Prevents Bacterial Toxin-Induced Septic Shock in Mice by Inducing IL-10 Expression

Journal of Immunology

Volumn 158, Issue 6, 1997, Pages 2856-2861

  Wang, Ruoxiang ^a   Fang, Qiding ^a   Zhang, Liying ^a   Radvany, Laszlo ^b   Sharma, Ajay ^a   Noben Trauth, Nancy ^c   Mills, Gordon B ^d   Shi, Yufang ^a  

^a HOLLAND LABORATORY   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD28 ANTIGEN; ENTEROTOXIN; ENTEROTOXIN B, STAPHYLOCOCCAL; INTERLEUKIN 10; LIPOPOLYSACCHARIDE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; IMMUNOLOGY; MALE; METABOLISM; MOUSE; PHYSIOLOGY; SEPTIC SHOCK; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES; ANTIGENS, CD28; ENTEROTOXINS; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS;

EID: 0031569098     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Baron, R. 1993. Pathophysiology of septic shock and implications for therapy. Clin. Pharm. 12:8298.
2. van der Poll, T., and S. F. Lowry. 1995. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 3:1.
3. Beutler, B. 1993. Endotoxin, tumor necrosis factor, and related mediators: new approaches to shock. New Horiz. 1:3.
4. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662.
5. Zanders, E. D., J. R. Lamb, M. Feldman, N. Green, and P. C. L. Beverlt. 1983. Tolerance of T cells is associated with membrane changes. Nature 303:625.
6. Hara, T., S. M. Fu, and J. A. Hansen. 1985. Human T cell activation. II: a new T cell activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44-kilodalton peptide (9.3 antigen). J. Exp. Med. 161:1513.
7. Ledbetter, J. A., P. J. Martin, C. E. Spooner, D. Wofsy, T. T. Tsu, P. G. Beatty, and P. Gladstone. 1985. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J. Immunol. 135:2331.
8. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191.
9. Gross, J. A., E. Callas, and J. P. Allison. 1992. Identification and distribution of the costimulaiory receptor CD28 in the mouse. J. Immunol. 149:380.
10. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793.
11. Green, J. M., and C. B. Thompson. 1994. Modulation of T cell proliferative response by accessory cell interactions. Immunol. Res. 13:234.
12. Shi, Y. F., L. Radvanyi, P. Shaw, D. R. Green, R. Miller, and G. B. Mills. 1995. CD28-mediated signaling in vivo prevents activation-induced apoptosis in the thymus and alters peripheral lymphocyte homeostasis. J. Immunol. 155:1829.
13. L. Immunity 3:87.
14. Lenschow, D. J., Y, Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4Ig. Science 257:789.
15. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kundig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609.
16. Mosmann, T. R., and R. L. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
17. Howard, M., T. Muchamuel, S. Andrade, and S. Menon. 1993. Interleukin-10 protects mice from septic shock. J. Exp. Med. 177:7205.
18. Pullen, J. K., and L. B. Schook. 1986. Bone marrow-derived macrophage expression of endogenous and transfected class II MHC genes during differentiation in vitro. J. Immunol. 137:1359.
19. Aggarwal, B. B., and W. J. Kohr. 1985. Human tumor necrosis factor. Methods Enzymol. 116:448.
20. Mosmann, T. R. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55.
21. Kotzin, B. L., D. Y. Leung, J. Kappler, and P. Marrack. 1993. Superantigens and their potential role in human disease. Adv. Immunol. 54:99.
22. Leist, M., F. Gantner, I. Bohlinger, P. G. Germann, and A. Wendel. 1994. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-α requires transcriptional arrest. J. Immunol. 153:1178.
23. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815.
24. Gérard, C., C. Bruyns, A. Marchant, D. Abramowicz, P. Vandenabeele, A. Delvaux, W. Fiers, M. Goldman, and T. Velu. 1993. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:547.
25. van der Poll, T., A. Marchant, W. A. Buurman, L. Berman, C. V. Keogh, D. D. Lazarus, L. Nguyen, M. Goldman, L. L. Moldawer, and S. F. Lowry. 1995. Endogenous IL-10 protects mice from death during septic peritonitis. J. Immunol. 155:5397.
26. Gerard, C., C. Bruyns, A. Marchant, D. Abramowicz, P. Vandenabeele, A. Delvaux, W. Fiers, M. Goldman, and T. Velu. 1993. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:547.
27. Standiford, T. I., R. M. Strieter, N. W. Lukacs, and S. L. Kunkel. 1995. Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J. Immunol. 155: 2222.
28. D'Andrea, A., M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and G. Trinchieri. 1993. Interieukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1041.
29. Oswald, I. P., T. A. Wynn, A. Sher, and S. L. James. 1992. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proc. Natl. Acad. Sci. USA 89:8676.
30. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815.
31. Mosmann, T. R., and K. W. Moore. 1991. The role of IL-10 in cross-regulation of TH1 and TH2 responses. Immunol. Today 12:A49.
32. Cunha, F. Q., S. Moncada, and F. Y. Liew. 1992. Interieukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. Biochem. Biophys. Res. Commun. 182:1155.
33. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
34. Wherry, J., R. Wenzel, R. Wunderlink, H. Silverman, T. Perl, and S. Nasraway. 1993. Monoclonal antibody to human tumor necrosis factor (TNF mAb): multicenter efficacy and safety in patients with the sepsis syndrome. In Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC. p. 246 (Abstr.).
35. Zell, T., S. W. Hunt III, J. L. Mobley, L. D. Finkelstein, and Y. Shimizu. 1996. CD28-mediated up-regulation of beta 1-integrin adhesion involves phosphatidylinositol 3-kinase. J. Immunol. 156:883.